Online citations, reference lists, and bibliographies.
← Back to Search

Prognostic Features Of Long-term Survivors After Surgical Management Of Malignant Pleural Mesothelioma.

T. Yan, M. Boyer, M. Tin, J. Sim, C. Kennedy, J. McLean, P. Bannon, B. McCaughan
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND The primary aim of this study was to evaluate prognostic features of long-term survivors with pleural mesothelioma. METHODS Overall survival outcome was analyzed in 456 patients with malignant pleural mesothelioma who underwent extrapleural pneumonectomy (EPP), pleurectomy/decortications, or pleurodesis/biopsy with at least 18 months of follow-up. Prospectively collected clinicopathologic and treatment data were assessed for their correlations with actual 18-month survivors in both univariate and multivariate analyses. RESULTS The actual 18-month survival was 28%. Epithelial subtype was present in 185 patients (41%) and nonepithelial subtype in 183 (40%). Procedures were EPP in 59 patients (13%), pleurectomy/decortication in 250 (55%), and pleurodesis/biopsy in 147 (32%). Forty-two patients (9%) underwent positron emission tomography (PET) scanning. Forty patients (9%) received adjuvant radiotherapy and 45 (10%) received postoperative pemetrexed combination chemotherapy. In univariate analysis, age 65 years or younger (p < 0.001), malignant pleural effusion (p = 0.041), epithelial subtype (p < 0.001), EPP (p < 0.001), PET scan (p = 0.012), adjuvant radiotherapy (p = 0.042), and postoperative pemetrexed combination chemotherapy (p = 0.035) were strongly associated with 18-month survivors. In multivariate analysis, epithelial histopathologic subtype (p < 0.001) and EPP (p < 0.001) were independently associated with 18-month survivors. CONCLUSIONS The actual 18-month survival was 28% in 456 pleural mesothelioma patients who underwent operation. Epithelial histologic subtype and EPP were identified as independent predictors for 18-month survivors.
This paper references
10.1016/S0169-5002(01)00257-4
Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma.
G. Ceresoli (2001)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1016/S1556-0864(15)31536-7
Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma.
D. Sugarbaker (2006)
Advances in malignant mesotheli
BW Robinson (2005)
10.5694/j.1326-5377.1991.tb121175.x
Pleurectomy for mesothelioma
R. Brancatisano (1991)
10.1093/ANNONC/MDM501
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
B. Castagneto (2008)
10.1093/AJE/KWH025
Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003.
B. Price (2004)
10.1016/S0140-6736(08)60727-8
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1016/S0360-3016(03)00287-6
Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma.
S. Yajnik (2003)
10.1016/J.JTCVS.2006.03.068
Positron emission tomography predicts survival in malignant pleural mesothelioma.
R. Flores (2006)



This paper is referenced by
10.3978/j.issn.2072-1439.2013.07.40
Which type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extended pleurectomy?
M. A. Bedirhan (2013)
Publications for Paul Bannon 2016
P. Bannon (2016)
10.1038/bjc.2014.478
Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales
A. Linton (2014)
10.1093/ejcts/ezt664
Predictors of long-term survival following radical surgery for malignant pleural mesothelioma.
A. Nakas (2014)
10.1967/s002449910162
Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature.
V. A. Marín-Oyaga (2015)
10.1245/s10434-010-1107-z
Volume-Based Parameter of 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications
H. Lee (2010)
10.3892/ol.2019.9979
Prolonged post-recurrence survival following pleurectomy/decortication for malignant pleural mesothelioma.
Yuichiro Kai (2019)
10.3390/jcm9072153
Should Lung-Sparing Surgery Be the Standard Procedure for Malignant Pleural Mesothelioma?
Y. Ichiki (2020)
10.1016/j.athoracsur.2014.09.056
Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma.
E. Taioli (2015)
10.1038/bjc.2012.44
First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial
Ó. Arrieta (2012)
10.1111/j.1445-5994.2010.02223.x
Malignant mesothelioma
S. Kao (2010)
10.1016/j.humpath.2020.02.007
Histopathological features of epithelioid malignant pleural mesotheliomas in patients with extended survival.
Juuso Paajanen (2020)
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
10.1097/JTO.0000000000000181
Supplementary Prognostic Variables for Pleural Mesothelioma
H. Pass (2014)
10.2147/LCTT.S102113
Clinical staging of malignant pleural mesothelioma: current perspectives
M. Bonomi (2017)
10.1016/j.athoracsur.2016.08.063
Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.
W. Vigneswaran (2017)
Best evidence topic - Thoracic oncologic Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
Sumera Sharif (2011)
10.1093/ICVTS/IVT372.331
331PREDICTORS OF LONG-TERM SURVIVAL FOLLOWING RADICAL SURGERY FOR MALIGNANT PLEURAL MESOTHELIOMA
A. Nakas (2013)
10.1097/JTO.0b013e3181ed0489
A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
C. Cao (2010)
10.1007/978-1-84996-492-0_48
Malignant Pleural Mesothelioma: Patient Selection for Extrapleural Pneumonectomy
D. Waller (2011)
10.1007/978-1-4471-6404-3_51
Surgical and Medical Therapy for Malignant Pleural Mesothelioma
C. Cao (2014)
10.1510/icvts.2010.255901
Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
S. Sharif (2011)
10.1111/1759-7714.12967
Characteristics and long‐term outcomes of advanced pleural mesothelioma in Latin America (MeSO‐CLICaP)
L. Rojas (2019)
10.1016/j.thorsurg.2016.04.003
Current Treatment of Mesothelioma: Extrapleural Pneumonectomy Versus Pleurectomy/Decortication.
A. Wolf (2016)
10.1016/j.path.2010.03.010
Benign and Malignant Mesothelial Proliferation.
E. H. Zeren (2010)
10.1093/icvts/ivs465
Multimodal therapy of malignant pleural mesothelioma: is the replacement of radical surgery imminent?
J. Lindenmann (2013)
Semantic Scholar Logo Some data provided by SemanticScholar